Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Butyrate production in patients with end-stage renal disease.

International journal of nephrology and renovascular disease

Terpstra ML, Sinnige MJ, Hugenholtz F, Peters-Sengers H, Remmerswaal EB, Geerlings SE, Bemelman FJ.
PMID: 31123416
Int J Nephrol Renovasc Dis. 2019 May 06;12:87-101. doi: 10.2147/IJNRD.S200297. eCollection 2019.

No abstract available.

Cite
Terpstra ML, Sinnige MJ, Hugenholtz F, et al. Butyrate production in patients with end-stage renal disease. Int J Nephrol Renovasc Dis. 2019;12:87-101doi: 10.2147/IJNRD.S200297.
Terpstra, M. L., Sinnige, M. J., Hugenholtz, F., Peters-Sengers, H., Remmerswaal, E. B., Geerlings, S. E., & Bemelman, F. J. (2019). Butyrate production in patients with end-stage renal disease. International journal of nephrology and renovascular disease, 1287-101. https://doi.org/10.2147/IJNRD.S200297
Terpstra, Matty L, et al. "Butyrate production in patients with end-stage renal disease." International journal of nephrology and renovascular disease vol. 12 (2019): 87-101. doi: https://doi.org/10.2147/IJNRD.S200297
Terpstra ML, Sinnige MJ, Hugenholtz F, Peters-Sengers H, Remmerswaal EB, Geerlings SE, Bemelman FJ. Butyrate production in patients with end-stage renal disease. Int J Nephrol Renovasc Dis. 2019 May 06;12:87-101. doi: 10.2147/IJNRD.S200297. eCollection 2019. PMID: 31123416; PMCID: PMC6510402.
Copy Download .nbib Format: NLM
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.

Transplantation

Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Frölke SC, Geers D, GeurtsvanKessel CH, den Hartog G, van der Heiden M, Imhof C, Kho MML, Koopmans MPG, Malahe SRK, Mattheussens WB, van der Molen R, van Mourik D, Remmerswaal EBM, Rots N, Vart P, de Vries RD, Gansevoort RT, Hilbrands LB, Reinders MEJ.
PMID: 34753894
Transplantation. 2021 Nov 09; doi: 10.1097/TP.0000000000003983. Epub 2021 Nov 09.

BACKGROUND: In kidney patients COVID-19 is associated with severely increased morbidity and mortality. A comprehensive comparison of the immunogenicity, tolerability, and safety of COVID-19 vaccination in different cohorts of kidney patients and a control cohort is lacking.METHODS: This investigator...

Cite
Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation. 2021;doi: 10.1097/TP.0000000000003983.
Sanders, J. F., Bemelman, F. J., Messchendorp, A. L., Baan, C. C., van Baarle, D., van Binnendijk, R., Diavatopoulos, D. A., Frölke, S. C., Geers, D., GeurtsvanKessel, C. H., den Hartog, G., van der Heiden, M., Imhof, C., Kho, M. M. L., Koopmans, M. P. G., Malahe, S. R. K., Mattheussens, W. B., van der Molen, R., van Mourik, D., Remmerswaal, E. B. M., Rots, N., Vart, P., de Vries, R. D., Gansevoort, R. T., Hilbrands, L. B., Reinders, M. E. J. (2021). The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation, . https://doi.org/10.1097/TP.0000000000003983
Sanders, Jan-Stephan F, et al. "The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant." Transplantation vol. (2021). doi: https://doi.org/10.1097/TP.0000000000003983
Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Frölke SC, Geers D, GeurtsvanKessel CH, den Hartog G, van der Heiden M, Imhof C, Kho MML, Koopmans MPG, Malahe SRK, Mattheussens WB, van der Molen R, van Mourik D, Remmerswaal EBM, Rots N, Vart P, de Vries RD, Gansevoort RT, Hilbrands LB, Reinders MEJ. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation. 2021 Nov 09; doi: 10.1097/TP.0000000000003983. Epub 2021 Nov 09. PMID: 34753894.
Copy Download .nbib Format: NLM
Monolithic All-Perovskite Tandem Solar Cells with Minimized Optical and Energetic Losses.

Advanced materials (Deerfield Beach, Fla.)

Datta K, Wang J, Zhang D, Zardetto V, Remmerswaal WHM, Weijtens CHL, Wienk MM, Janssen RAJ.
PMID: 34965005
Adv Mater. 2021 Dec 29;e2110053. doi: 10.1002/adma.202110053. Epub 2021 Dec 29.

Perovskite-based multijunction solar cells are a potentially cost-effective technology that can help surpass the efficiency limits of single-junction devices. However, both mixed-halide wide-bandgap perovskites and lead-tin narrow-bandgap perovskites suffer from non-radiative recombination due to the formation of bulk traps...

Cite
Datta K, Wang J, Zhang D, et al. Monolithic All-Perovskite Tandem Solar Cells with Minimized Optical and Energetic Losses. Adv Mater. 2021;e2110053doi: 10.1002/adma.202110053.
Datta, K., Wang, J., Zhang, D., Zardetto, V., Remmerswaal, W. H. M., Weijtens, C. H. L., Wienk, M. M., & Janssen, R. A. J. (2021). Monolithic All-Perovskite Tandem Solar Cells with Minimized Optical and Energetic Losses. Advanced materials (Deerfield Beach, Fla.), e2110053. https://doi.org/10.1002/adma.202110053
Datta, Kunal, et al. "Monolithic All-Perovskite Tandem Solar Cells with Minimized Optical and Energetic Losses." Advanced materials (Deerfield Beach, Fla.) vol. (2021): e2110053. doi: https://doi.org/10.1002/adma.202110053
Datta K, Wang J, Zhang D, Zardetto V, Remmerswaal WHM, Weijtens CHL, Wienk MM, Janssen RAJ. Monolithic All-Perovskite Tandem Solar Cells with Minimized Optical and Energetic Losses. Adv Mater. 2021 Dec 29;e2110053. doi: 10.1002/adma.202110053. Epub 2021 Dec 29. PMID: 34965005.
Copy Download .nbib Format: NLM
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Kho MML, Reinders MEJ, Baan CC, van Baarle D, Bemelman FJ, Diavatopoulos DA, Gansevoort RT, van der Klis FRM, Koopmans MPG, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Rots N, Vart P, de Vries RD, Hilbrands LB, Sanders JF.
PMID: 34038554
Nephrol Dial Transplant. 2021 May 26; doi: 10.1093/ndt/gfab186. Epub 2021 May 26.

No abstract available.

Cite
Kho MML, Reinders MEJ, Baan CC, et al. The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium. Nephrol Dial Transplant. 2021;doi: 10.1093/ndt/gfab186.
Kho, M. M. L., Reinders, M. E. J., Baan, C. C., van Baarle, D., Bemelman, F. J., Diavatopoulos, D. A., Gansevoort, R. T., van der Klis, F. R. M., Koopmans, M. P. G., Messchendorp, A. L., van der Molen, R. G., Remmerswaal, E. B. M., Rots, N., Vart, P., de Vries, R. D., Hilbrands, L. B., Sanders, J. F. (2021). The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, . https://doi.org/10.1093/ndt/gfab186
Kho, Marcia M L, et al. "The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium." Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association vol. (2021). doi: https://doi.org/10.1093/ndt/gfab186
Kho MML, Reinders MEJ, Baan CC, van Baarle D, Bemelman FJ, Diavatopoulos DA, Gansevoort RT, van der Klis FRM, Koopmans MPG, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Rots N, Vart P, de Vries RD, Hilbrands LB, Sanders JF. The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - a prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium COVID-19 VACcination (RECOVAC) consortium. Nephrol Dial Transplant. 2021 May 26; doi: 10.1093/ndt/gfab186. Epub 2021 May 26. PMID: 34038554.
Copy Download .nbib Format: NLM
The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose.

Frontiers in immunology

Redeker A, Remmerswaal EBM, van der Gracht ETI, Welten SPM, Höllt T, Koning F, Cicin-Sain L, Nikolich-Žugich J, Ten Berge IJM, van Lier RAW, van Unen V, Arens R.
PMID: 29367854
Front Immunol. 2018 Jan 10;8:1953. doi: 10.3389/fimmu.2017.01953. eCollection 2017.

The relationship between human cytomegalovirus (HCMV) infections and accelerated immune senescence is controversial. Whereas some studies reported a CMV-associated impaired capacity to control heterologous infections at old age, other studies could not confirm this. We hypothesized that these discrepancies...

Cite
Redeker A, Remmerswaal EBM, van der Gracht ETI, et al. The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. Front Immunol. 2018;8:1953doi: 10.3389/fimmu.2017.01953.
Redeker, A., Remmerswaal, E. B. M., van der Gracht, E. T. I., Welten, S. P. M., Höllt, T., Koning, F., Cicin-Sain, L., Nikolich-Žugich, J., Ten Berge, I. J. M., van Lier, R. A. W., van Unen, V., & Arens, R. (2017). The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. Frontiers in immunology, 81953. https://doi.org/10.3389/fimmu.2017.01953
Redeker, Anke, et al. "The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose." Frontiers in immunology vol. 8 (2017): 1953. doi: https://doi.org/10.3389/fimmu.2017.01953
Redeker A, Remmerswaal EBM, van der Gracht ETI, Welten SPM, Höllt T, Koning F, Cicin-Sain L, Nikolich-Žugich J, Ten Berge IJM, van Lier RAW, van Unen V, Arens R. The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. Front Immunol. 2018 Jan 10;8:1953. doi: 10.3389/fimmu.2017.01953. eCollection 2017. PMID: 29367854; PMCID: PMC5768196.
Copy Download .nbib Format: NLM
Payment schemes and treatment responses after a demand shock in mental health care.

Health economics

Douven R, Remmerswaal M, Vervliet T.
PMID: 34494334
Health Econ. 2021 Dec;30(12):2956-2973. doi: 10.1002/hec.4417. Epub 2021 Sep 07.

We study whether two groups of mental health care providers-each paid according to a different payment scheme-adjusted the duration of their patients' treatments after they faced an exogenous 20% drop in the number of patients. For the first group...

Cite
Douven R, Remmerswaal M, Vervliet T. Payment schemes and treatment responses after a demand shock in mental health care. Health Econ. 2021;30(12):2956-2973doi: 10.1002/hec.4417.
Douven, R., Remmerswaal, M., & Vervliet, T. (2021). Payment schemes and treatment responses after a demand shock in mental health care. Health economics, 30(12), 2956-2973. https://doi.org/10.1002/hec.4417
Douven, Rudy, et al. "Payment schemes and treatment responses after a demand shock in mental health care." Health economics vol. 30,12 (2021): 2956-2973. doi: https://doi.org/10.1002/hec.4417
Douven R, Remmerswaal M, Vervliet T. Payment schemes and treatment responses after a demand shock in mental health care. Health Econ. 2021 Dec;30(12):2956-2973. doi: 10.1002/hec.4417. Epub 2021 Sep 07. PMID: 34494334.
Copy Download .nbib Format: NLM
The Transcription Factor Hobit Identifies Human Cytotoxic CD4.

Frontiers in immunology

Oja AE, Vieira Braga FA, Remmerswaal EB, Kragten NA, Hertoghs KM, Zuo J, Moss PA, van Lier RA, van Gisbergen KP, Hombrink P.
PMID: 28392788
Front Immunol. 2017 Mar 24;8:325. doi: 10.3389/fimmu.2017.00325. eCollection 2017.

The T cell lineage is commonly divided into CD4-expressing helper T cells that polarize immune responses through cytokine secretion and CD8-expressing cytotoxic T cells that eliminate infected target cells by virtue of the release of cytotoxic molecules. Recently, a...

Cite
Oja AE, Vieira Braga FA, Remmerswaal EB, et al. The Transcription Factor Hobit Identifies Human Cytotoxic CD4. Front Immunol. 2017;8:325doi: 10.3389/fimmu.2017.00325.
Oja, A. E., Vieira Braga, F. A., Remmerswaal, E. B., Kragten, N. A., Hertoghs, K. M., Zuo, J., Moss, P. A., van Lier, R. A., van Gisbergen, K. P., & Hombrink, P. (2017). The Transcription Factor Hobit Identifies Human Cytotoxic CD4. Frontiers in immunology, 8325. https://doi.org/10.3389/fimmu.2017.00325
Oja, Anna E, et al. "The Transcription Factor Hobit Identifies Human Cytotoxic CD4." Frontiers in immunology vol. 8 (2017): 325. doi: https://doi.org/10.3389/fimmu.2017.00325
Oja AE, Vieira Braga FA, Remmerswaal EB, Kragten NA, Hertoghs KM, Zuo J, Moss PA, van Lier RA, van Gisbergen KP, Hombrink P. The Transcription Factor Hobit Identifies Human Cytotoxic CD4. Front Immunol. 2017 Mar 24;8:325. doi: 10.3389/fimmu.2017.00325. eCollection 2017. PMID: 28392788; PMCID: PMC5364140.
Copy Download .nbib Format: NLM
Functional Differences Between EBV- and CMV-Specific CD8.

HemaSphere

Hofland T, de Weerdt I, Endstra S, Jongejan A, Platenkamp L, Remmerswaal EBM, Moerland PD, Ten Berge IJM, Levin MD, Kater AP, Tonino SH.
PMID: 32309780
Hemasphere. 2020 Feb 13;4(2):e337. doi: 10.1097/HS9.0000000000000337. eCollection 2020 Apr.

Acquired T cell dysfunction is a hallmark of chronic lymphocytic leukemia (CLL), and is linked to an increased risk of infections, but also reduced immune surveillance and disappointing responses to autologous T cell-based immunotherapy. The mechanisms of T cell...

Cite
Hofland T, de Weerdt I, Endstra S, et al. Functional Differences Between EBV- and CMV-Specific CD8. Hemasphere. 2020;4(2):e337doi: 10.1097/HS9.0000000000000337.
Hofland, T., de Weerdt, I., Endstra, S., Jongejan, A., Platenkamp, L., Remmerswaal, E. B. M., Moerland, P. D., Ten Berge, I. J. M., Levin, M. D., Kater, A. P., & Tonino, S. H. (2020). Functional Differences Between EBV- and CMV-Specific CD8. HemaSphere, 4(2), e337. https://doi.org/10.1097/HS9.0000000000000337
Hofland, Tom, et al. "Functional Differences Between EBV- and CMV-Specific CD8." HemaSphere vol. 4,2 (2020): e337. doi: https://doi.org/10.1097/HS9.0000000000000337
Hofland T, de Weerdt I, Endstra S, Jongejan A, Platenkamp L, Remmerswaal EBM, Moerland PD, Ten Berge IJM, Levin MD, Kater AP, Tonino SH. Functional Differences Between EBV- and CMV-Specific CD8. Hemasphere. 2020 Feb 13;4(2):e337. doi: 10.1097/HS9.0000000000000337. eCollection 2020 Apr. PMID: 32309780; PMCID: PMC7162091.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries